In vitro–in vivo extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects

References

• Artursson P, Borchardt RT. Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond. Pharmaceutical Research 1997; 14(12)1655–1658
   PubMed Web of Science ®Google Scholar
• Austin RP, Barton P, Mohmed S, Riley RJ. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metabolism and Disposition 2005; 33(3)419–425
   PubMed Web of Science ®Google Scholar
• Bi Y, Kazolias D, Duignan DB. Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metabolism and Disposition 2006; 34: 1658–1665
   PubMed Web of Science ®Google Scholar
• Cattori V, Van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, Meier PJ, Hagenbuch B. Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Archiv — European Journal of Physiology 2001; 443(2)188–195
   PubMed Web of Science ®Google Scholar
• Chou C, McLachlan AJ, Rowland M. Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethylbarbituric acid and other compounds. Journal of Pharmacology and Experimental Therapeutics 1995; 275(2)933–940
   PubMedGoogle Scholar
• Cui Y, Konig J, Keppler D. Vectorial transport by double-transfected cells expressing the human uptake transporter SLC21A8 and the apical export pump ABCC2. Molecular Pharmacology 2001; 60(5)934–943
   PubMed Web of Science ®Google Scholar
• De Lannoy IAM, Pang KS. Effect of diffusional barriers on drug and metabolite kinetics. Drug Metabolism and Disposition 1987; 33(3)51–58
   Google Scholar
• Eckhardt U, Schroeder A, Stieger B, Hochli M, Landmann L, Tynes R, Meier PJ, Hagenbuch B. Polyspecific substrate uptake by the hepatic organic anion transporter Oatp1 in stably transfected CHO cells. American Journal of Physiology 1999; 276(4 Pt 1)G1037–G1042
   Google Scholar
• Evans AM. Membrane transport as a determinant of the hepatic elimination of drugs and metabolites. Clinical and Experimental Pharmacology and Physiology 1996; 23(10-11)970–974
   PubMed Web of Science ®Google Scholar
• Frézard F, Garnier-Suillerot A. Permeability of lipid bilayer to anthracycline derivatives. Role of the bilayer composition and of the temperature. Biochimica et Biophysica Acta (BBA) — Lipids and Lipid Metabolism 1998; 1389(1)13–22
   PubMedGoogle Scholar
• Ghibellini G, Vasist LS, Leslie EM, Heizer WD, Kowalsky RJ, Calvo BF, Brouwer KL. In vitro–in vivo correlation of hepatobiliary drug clearance in humans. Clinical Pharmacology and Therapeutics 2007; 81(3)406–413
   PubMed Web of Science ®Google Scholar
• Gibaldi M, Perrier D. Pharmacokinetics. Marcel Dekker, New York, NY 1975
   Google Scholar
• Gillette JR. Factors affecting drug metabolism. Annals of the New York Academy of Sciences 1971; 179: 43–66
   PubMed Web of Science ®Google Scholar
• Grime K, Riley RJ. The impact of in vitro binding on in vitro-in vivo extrapolations, projections of metabolic clearance and clinical drug-drug interactions. Current Drug Metabolism 2006; 7(3)251–264
   PubMed Web of Science ®Google Scholar
• Hagenbuch B, Meier PJ. Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. Journal of Clinical Investigation 1994; 93(3)1326–1331
   PubMedGoogle Scholar
• Hagenbuch B, Meier PJ. The superfamily of organic anion transporting polypeptides. Biochimica et Biophysica Acta 2003; 1609: 1–18
   PubMed Web of Science ®Google Scholar
• Hallifax D, Houston JB. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metabolism and Disposition 2006; 34(11)1829–1836
   PubMedGoogle Scholar
• Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends in Pharmacological Sciences 1998; 19(1)26–37
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Sugiyama Y. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. Journal of Pharmacology and Experimental Therapeutics 2004; 311(1)139–146
   PubMed Web of Science ®Google Scholar
• Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, Brouwer KLR. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2,D-Pen5]-enkepalin (DPDPE): Pharmacokinetic consequences of the interplay between multiple transport systems. Journal of Pharmacology and Experimental Therapeutics 2004; 311(3)1203–1210
   PubMedGoogle Scholar
• Ishigami M, Tokui T, Komai T, Tsukahara K, Yamazaki M, Sugiyama Y. Evaluation of the uptake of pravastatin by perfused rat liver and primary cultured rat hepatocytes. Pharmaceutical Research 1995; 12(11)1741–1746
   PubMedGoogle Scholar
• Ito K, Houston JB. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharmaceutical Research 2004; 21(5)785–792
   PubMed Web of Science ®Google Scholar
• Ito K, Houston JB. Prediction of human drug clearance from in vitro and preclinical data using physiologically based and empirical approaches. Pharmaceutical Research 2005; 22(1)103–112
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Hirota N, Ooie T, Suzuki H, Sugiyama Y. Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharmaceutics and Drug Disposition 1996; 17(4)273–310
   PubMed Web of Science ®Google Scholar
• Iwatsubo T, Suzuki H, Sugiyama Y. Determination of the rate-limiting step in the hepatic elimination of YM796 by isolated rat hepatocytes. Pharmaceutical Research 1999; 16(1)110–116
   PubMedGoogle Scholar
• Jorgensen L, Van Beek J, Lund S, Schousboe A, Badolo L. Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes. European Journal of Pharmaceutical Sciences 2007; 30(2)181–189
   PubMed Web of Science ®Google Scholar
• Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15 + C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenetics and Genomics 2005; 15(7)513–522
   PubMed Web of Science ®Google Scholar
• Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: Parallel artificial membrane permeation assay in the description of passive absorption processes. Journal of Medicinal Chemistry 1998; 41(7)1007–1010
   PubMed Web of Science ®Google Scholar
• Keppler D, Konig J. Hepatic secretion of conjugated drugs and endogenous substances. Seminars in Liver Disease 2000; 20: 265–272
   PubMed Web of Science ®Google Scholar
• König J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn–Schmiedeberg's Archives of Pharmacology 2007; 372(6)432–443
   Google Scholar
• Kouzuki H, Suzuki H, Ito K, Ohashi R, Sugiyama Y. Contribution of organic anion transporting polypeptide to uptake of its possible substrates into rat hepatocytes. Journal of Pharmacology and Experimental Therapeutics. 1999; 288(2)627–634
   PubMedGoogle Scholar
• Kusuhara H, Sekine T, Utsunomiya-Tate N, Tsuda M, Kojima R, Cha SH, Sugiyama Y, Kanai Y, Endou H. Molecular cloning and characterization of a new multispecific organic anion transporter from rat brain. Journal of Biological Chemistry 1999; 274(19)13675–13680
   PubMedGoogle Scholar
• Lam JL, Benet LZ. Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug–drug interactions: Studies of digoxin metabolism in primary rat hepatocytes versus microsomes. Drug Metabolism and Disposition 2004; 32(11)1311–1316
   PubMed Web of Science ®Google Scholar
• Lam JL, Okochi H, Huang Y, Benet LZ. In vitro and in vivo correlation of hepatic transporter effects on erythromycin metabolism: Characterizing the importance of transporter–enzyme interplay. Drug Metabolism and Disposition 2006; 34(8)1336–1344
   PubMedGoogle Scholar
• Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: Relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metabolism and Disposition 2006; 34(7)1175–1181
   PubMedGoogle Scholar
• Le Couteur DG, Fraser R, Hilmer S, Rivory LP, McLean AJ. The hepatic sinusoid in aging and cirrhosis. Clinical Pharmacokinetics 2005; 44(2)187–200
   PubMedGoogle Scholar
• Li AP, Lu C, Brent JA, Pham C, Fackett A, Ruegg CE, Silber PM. Cryopreserved human hepatocytes: Characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug–drug interaction potential. Chemico-Biological Interactions 1999; 121: 17–35
   PubMed Web of Science ®Google Scholar
• Liu L, Pang KS. The roles of transporters and enzymes in hepatic drug processing. Drug Metabolism and Disposition 2005; 33(1)1–9
   PubMed Web of Science ®Google Scholar
• Lu C, Li P, Gallegos R, Uttamsingh V, Xia CQ, Miwa GT, Balani SK, Gan LS. Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: Evaluation of free fraction and uptake in hepatocytes. Drug Metabolism and Disposition 2006; 34: 1600–1605
   PubMed Web of Science ®Google Scholar
• Luttringer O, Theil FP, Lave T, Wernli-Kuratli K, Guentert TW, De Saizieu A. Biochemical Influence of isolation procedure, extracellular matrix and dexamethasone on the regulation of membrane transporters gene expression in rat hepatocytes. Pharmacology 2002; 64(11)1637–1650
   Google Scholar
• Marzolini C, Tirona RG, Kim RB. Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 2004; 5(3)273–282
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Kondo C, Hirano M, Sasaki M, Suzuki H, Sugiyama Y. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin–Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. Journal of Pharmacology and Experimental Therapeutics 2005; 314(3)1059–1067
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Parker AJ, Soars M, Riley RJ. Automated definition of the enzymology of drug oxidation by the major human drug metabolizing cytochrome P450s. Drug Metabolism and Disposition 2000; 28(11)1327–1334
   PubMed Web of Science ®Google Scholar
• McGinnity DF, Riley RJ. Predicting drug pharmacokinetics in humans from in vitro metabolism studies. Biochemical Society Transactions 2001; 29(2)135–139
   PubMedGoogle Scholar
• McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metabolism and Disposition 2004; 32(11)1247–1253
   PubMed Web of Science ®Google Scholar
• Meier PJ, Eckhardt U, Schroeder A, Hagenbuch B, Stieger B. Substrate specificity of sinusoidal bile acid and organic anion uptake systems in rat and human liver. Hepatology 1997; 26: 1667–1677
   PubMed Web of Science ®Google Scholar
• Miyauchi S, Sugiyama Y, Sawada Y, Morita K, Iga T, Hanano M. Kinetics of hepatic transport of 4-methylumbelliferone in rats. Analysis by multiple indicator dilution method. Journal of Pharmacokinetics and Pharmacodynamics 1987; 15(1)25–38
   Google Scholar
• Nakajima M, Nakamura S, Tokudome S, Shimada N, Yamazaki H, Yokoi T. Azelastine N-demethylation by cytochrome P-450 (CYP)3A4, CYP2D6, and CYP1A2 in human liver microsomes: Evaluation of approach to predict the contribution of multiple CYPs. Drug Metabolism and Disposition 1999; 27: 1381–1391
   PubMed Web of Science ®Google Scholar
• Nakamura H, Sano H, Yamazaki M, Sugiyama Y. Carrier-mediated active transport of histamine H2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes. Contribution of a Type 1 system. Journal of Pharmacology and Experimental Therapeutics 1994; 132: 103–109
   Google Scholar
• Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments an in vitro metabolic studies with liver microsomes from animals and humans. Drug metabolism and Disposition 2001; 29(10)1316–1324
   PubMed Web of Science ®Google Scholar
• Noe B, Hagenbuch B, Stieger B, Meier PJ. Isolation of a multispecific organic anion and cardiac glycoside transporter from rat brain. Proceedings of the National Academy of Sciences. USA 1997; 10346–10350, 94(19)
   Google Scholar
• Petzinger E, Fuckel D. Evidence for a saturable, energy dependent and carrier-mediated uptake of oral antidiabetics into rat hepatocytes. European Journal of Pharmacology 1992; 213: 381–391
   PubMedGoogle Scholar
• Proctor NJ, Tucker GT, Rostami-Hodjegan A. Predicting drug clearance from recombinantly expressed CYPs: Intersystem extrapolation factors. Xenobiotica 2004; 34(2)151–178
   PubMed Web of Science ®Google Scholar
• Reinoso RF, Telfer BA, Brennan BS, Rowland M. Uptake of teicoplanin by isolated rat hepatocytes: Comparison with in vivo hepatic distribution. Drug Metabolism and Disposition 2001; 29: 453–459
   PubMed Web of Science ®Google Scholar
• Riley RJ, McGinnity DF, Austin RP. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocytes and microsomes. Drug Metabolism and Disposition 2005; 33(9)1304–1311
   PubMed Web of Science ®Google Scholar
• Rostami-Hodjegan A, Tucker GT. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews Drug Discovery 2007; 6(2)140–148
   PubMed Web of Science ®Google Scholar
• Rowland M, Benet LZ, Graham GG. Clearance concepts in pharmacokinetics. Journal of Pharmacokinetics and Pharmacodynamics 1973; 1(1)123–136
   Google Scholar
• Rowland M, Tucker G. Pharmacokinetics: Theory and methodology. Oxford, Pergammon 1986
   Google Scholar
• Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, Hagenbuch B. Substrate specificity of the rat liver Na(+)-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. American Journal of Physiology 1998; 274(2 Pt 1)G370–G375
   Google Scholar
• Schwarz LR, Schwenk M, Pfaff E, Greim H. Excretion of taurocholate from isolated hepatocytes. European Journal of Biochemistry 1976; 71(2)369–373
   PubMedGoogle Scholar
• Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. European Journal of Pharmaceutical Sciences 2006; 27(5)425–446
   PubMed Web of Science ®Google Scholar
• Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y. Function of uptake transporters for taurocholate and estradiol 17ß-D-glucuronide in cryopreserved human hepatocytes. Drug Metabolism and Pharmacokinetics 2003; 18(1)33–41
   PubMedGoogle Scholar
• Shitara Y, Sato H, Sugiyama Y. Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annual Review of Pharmacology and Toxicology 2005; 45: 689–723
   PubMed Web of Science ®Google Scholar
• Sirianni GL, Pang KS. Organ clearance concepts: New perspectives on old principles. Journal of Pharmacokinetics and Biopharmacology 1997; 25(4)449–470
   PubMedGoogle Scholar
• Smith DA, Obach RS. Seeing through the mist: Abundance versus percentage. Commentary on metabolites in safety testing. Drug Metabolism and Disposition 2005; 33(10)1409–1417
   PubMedGoogle Scholar
• Soars MG, Burchell B, Riley RJ. In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. Journal of Pharmacology and Experimental Therapeutics 2002; 301(1)382–390
   PubMed Web of Science ®Google Scholar
• Soars MG, Gelboin HV, Krausz KW, Riley RJ. A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology. British Journal of Clinical Pharmacology 2003; 55(2)175–181
   PubMedGoogle Scholar
• Soars MG, Grime K, Sproston JL, Webborn PJ, Riley RJ. Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metabolism and Disposition 2007b; 35(6)859–865
   PubMed Web of Science ®Google Scholar
• Soars MG, McGinnity DF, Grime K, Riley RJ. The pivotal role of hepatocytes in drug discovery. Chemico-Biological Interactions 2007a; 168(1)2–15
   PubMed Web of Science ®Google Scholar
• Stormer E, Von Moltke LL, Greenblatt DJ. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. Journal of Pharmacology and Experimental Therapeutics 2000; 295: 793–801
   PubMed Web of Science ®Google Scholar
• Turncliff RZ, Hoffmaster KA, Kalvass JC, Pollack GM, Brouwer KLR. Hepatobiliary disposition of a drug/metabolite pair: Comprehensive pharmacokinetic modelling in sandwich-cultured rat hepatocytes. Journal of Pharmacology and Experimental Therapeutics 2006; 318(2)881–889
   PubMed Web of Science ®Google Scholar
• Ueda K, Kato Y, Komatsu K, Sugiyama Y. Inhibition of biliary excretion of methotrexate by probenecid in rats: Quantitative prediction of interaction from in vitro data. Journal of Pharmacology and Experimental Therapeutics 2001; 297(3)1036–1043
   PubMed Web of Science ®Google Scholar
• Van de Waterbeemd H, Smith DA, Jones BC. Lipophilicity in PK design: Methyl, ethyl, futile. Journal of Computer Aided Molecular Design 2001; 15: 273–286
   PubMed Web of Science ®Google Scholar
• Wenlock MC, Austin RP, Barton P, Davis AM, Leeson PD. A comparison of physiochemical property profiles of development and marketed oral drugs. Journal of Medicinal Chemistry 2003; 46(7)1250–1256
   PubMed Web of Science ®Google Scholar
• Wilkinson GR. Clearance approaches in pharmacology. Pharmacological Reviews 1987; 39: 1–47
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. Commentary: A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 1975; 18(4)377–390
   PubMed Web of Science ®Google Scholar
• Wu C-Y, Benet LZ. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research 2005; 22: 1–23
   PubMedGoogle Scholar
• Yamazaki M, Suzuki H, Hanano M, Tokui T, Sugiyama Y. Na+-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. American Journal of Physiology 1993; 264: G36–G44
   PubMed Web of Science ®Google Scholar